Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Acquisition of development stage CardioGene Therapeutics gives the Natick, Massachusetts firm a foothold in the gene therapy market for cardiovascular diseases such as angiogenesis, restenosis and congestive heart failure. Boston Scientific the purchases all outstanding stock in the Princeton, New Jersey firm, which holds patent positions covering the "use of device technology for delivery of genetic material to sites within the vasculature and the myocardium"